(Q50285020)

1 March 2018

title

Pre-existing anti-polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer (English)

1 reference

1 March 2018

1 reference

4

John H Alexander

1 reference

1 March 2018

author name string

Nancy J Ganson

1

1 reference

1 March 2018

Thomas J Povsic

2

1 reference

1 March 2018

Bruce A Sullenger

3

1 reference

1 March 2018

Steven L Zelenkofske

5

1 reference

1 March 2018

Jeffrey M Sailstad

6

1 reference

1 March 2018

Christopher P Rusconi

7

1 reference

1 March 2018

Michael S Hershfield

8

1 reference

1 March 2018

language of work or name

English

0 references

publication date

11 December 2015

1 reference

1 March 2018

The Journal of Allergy and Clinical Immunology

published in

1 reference

1 March 2018

volume

137

1 reference

1 March 2018

issue

5

1 reference

1 March 2018

page(s)

1610-1613.e7

1 reference

1 March 2018

Modulation of the Coagulation Cascade Using Aptamers

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5819876

Therapeutic outcomes, assessments, risk factors and mitigation efforts of immunogenicity of therapeutic protein products.

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5819876

Anti-PEG immunity: emergence, characteristics, and unaddressed questions

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5819876

Single-dose, subcutaneous recombinant phenylalanine ammonia lyase conjugated with polyethylene glycol in adult patients with phenylketonuria: an open-label, multicentre, phase 1 dose-escalation trial

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5819876

Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5819876

Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5819876

A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5819876

Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5819876

Aptamers: an emerging class of therapeutics

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5819876

10.1016/J.JACI.2015.10.034

22 May 2018

Identifiers

DOI

1 reference

1 March 2018

PMC publication ID

5819876

1 reference

1 March 2018

PubMed publication ID

26688515

1 reference

1 March 2018